People in Mosul, Iraq faced many acts of violence between 2014 and 2017 when the city was seized by the terrorist group of Islamic State of Iraq and Syria (ISIS). We aimed to determine the prevalence of symptoms of posttraumatic stress disorder (PTSD) among university students in Mosul. This cross-sectional study was conducted between the period of 15 April and 29 December 2020. Data were collected from 305 university students by face-to-face interview. The Iraqi modified version of the Harvard Trauma Questionnaire was used to assess the prevalence and degree of PTSD symptoms.

Recent research offers good reason to think that various psychedelic drugs—including psilocybin, ayahuasca, ketamine, MDMA, and LSD—may have significant therapeutic potential in the treatment of various mental health conditions, including post-traumatic stress disorder, depression, existential distress, and addiction. Although the use of psychoactive drugs, such as Diazepam or Ritalin, is well established, psychedelics arguably represent a therapeutic step change. As experiential therapies, their value would seem to lie in the subjective experiences they induce.

Post-traumatic stress disorder (PTSD) is associated with cognitive dysfunctions and is an independent risk factor for dementia. A recent study has found the prevalence of PTSD in people with dementia is 4.7%–7.8%. However, little is known about the effectiveness of PTSD treatment for people with dementia. The primary aim of the current study is to review previous studies on the treatment of PTSD in people with dementia.

Objective
This randomized-waitlist controlled trial is the first study examining short-term effects of a self-guided online grief-specific cognitive behavioral therapy (CBT) in reducing early persistent complex bereavement disorder (PCBD), posttraumatic stress disorder (PTSD), and depression symptoms in adults bereaved during the COVID-19 pandemic.